# Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

> **NCT06842199** · PHASE3 · RECRUITING · sponsor: **Beijing InnoCare Pharma Tech Co., Ltd.** · enrollment: 383 (estimated)

## Conditions studied

- Plaque Psoriasis Patients

## Interventions

- **DRUG:** ICP-488 Tablets
- **DRUG:** ICP-488 Placebo

## Key facts

- **NCT ID:** NCT06842199
- **Lead sponsor:** Beijing InnoCare Pharma Tech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-20
- **Primary completion:** 2026-05
- **Final completion:** 2027-02
- **Target enrollment:** 383 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06842199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06842199, "Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06842199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*